LEGN Stock Overview
A clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for LEGN from our risk checks.
Legend Biotech Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.14 |
| 52 Week High | US$70.13 |
| 52 Week Low | US$36.92 |
| Beta | 0.11 |
| 11 Month Change | -7.62% |
| 3 Month Change | -30.05% |
| 1 Year Change | -33.22% |
| 33 Year Change | -27.07% |
| 5 Year Change | n/a |
| Change since IPO | 8.49% |
Recent News & Updates
Recent updates
Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 15
Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
Sep 18Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking
Aug 01Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges
Jul 30Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt
Jul 05Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances
May 14Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio
May 13Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)
Mar 15Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Mar 06Legend Biotech: Solid Traction With Carvykti Rollout
Jan 29Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up
Jan 16Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Nov 09Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?
Apr 12An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued
Dec 14Legend Biotech wins approval of Carvykti for multiple myeloma in Japan
Sep 27Legend Biotech stock slides on proposed ADS offering
Jul 25Legend Biotech ends Phase 1 trial for lymphoma candidate
Jul 07News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts
Jun 05Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?
May 14Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results
Mar 22Legend Biotech: Carvykti Approval Makes For A Buy Opportunity
Mar 04Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be
Mar 03Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?
Dec 30Shareholder Returns
| LEGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.0% | -7.5% | -1.2% |
| 1Y | -33.2% | 14.1% | 30.4% |
Return vs Industry: LEGN underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: LEGN underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| LEGN volatility | |
|---|---|
| LEGN Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LEGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LEGN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 2,400 | Ying Huang | www.legendbiotech.com |
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel.
Legend Biotech Corporation Fundamentals Summary
| LEGN fundamental statistics | |
|---|---|
| Market cap | US$7.04b |
| Earnings (TTM) | -US$348.13m |
| Revenue (TTM) | US$520.18m |
14.2x
P/S Ratio-21.2x
P/E RatioIs LEGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LEGN income statement (TTM) | |
|---|---|
| Revenue | US$520.18m |
| Cost of Revenue | US$607.90m |
| Gross Profit | -US$87.72m |
| Other Expenses | US$260.41m |
| Earnings | -US$348.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.90 |
| Gross Margin | -16.86% |
| Net Profit Margin | -66.92% |
| Debt/Equity Ratio | 26.6% |
How did LEGN perform over the long term?
See historical performance and comparison